Combination of M7824 with Ox/5-FU was tested in the MC38 colorectal cancer model, with cisplatin, doxorubicin, radiation therapy (RT), or anti-VEGF A (B20) in the 4T1 breast cancer model, with gemcitabine in the MB49 bladder cancer model, with pazopanib in the RENCA renal carcinoma model, and with anti-CTLA4 in the B16 melanoma model. Here, CTLA4 is linked to breast carcinoma.